Santhera Pharmaceuticals (Switzerland) Buy Hold or Sell Recommendation
| SANN Stock | CHF 9.00 0.73 8.83% |
Assuming the 90 days trading horizon and your above-average risk tolerance, our recommendation regarding Santhera Pharmaceuticals Holding is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Santhera Pharmaceuticals Holding given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Santhera Pharmaceuticals Holding, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Santhera Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Santhera and provide practical buy, sell, or hold advice based on investors' constraints. Santhera Pharmaceuticals Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Santhera |
Execute Santhera Pharmaceuticals Buy or Sell Advice
The Santhera recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Santhera Pharmaceuticals Holding. Macroaxis does not own or have any residual interests in Santhera Pharmaceuticals Holding or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Santhera Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Santhera Pharmaceuticals Trading Alerts and Improvement Suggestions
| Santhera Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Santhera Pharmaceuticals has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Net Loss for the year was (55.53 M) with loss before overhead, payroll, taxes, and interest of (5.36 M). | |
| Santhera Pharmaceuticals Holding has accumulated about 21.21 M in cash with (37.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.07. | |
| Roughly 19.0% of the company outstanding shares are owned by corporate insiders |
Santhera Pharmaceuticals Returns Distribution Density
The distribution of Santhera Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Santhera Pharmaceuticals' future price movements. The chart of the probability distribution of Santhera Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Santhera Pharmaceuticals Holding price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Santhera Pharmaceuticals returns is essential to provide solid investment advice for Santhera Pharmaceuticals.
| Mean Return | -0.09 | Value At Risk | -3.47 | Potential Upside | 3.36 | Standard Deviation | 2.43 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Santhera Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Santhera Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Santhera Pharmaceuticals or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Santhera Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Santhera stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.12 | |
β | Beta against Dow Jones | 0.17 | |
σ | Overall volatility | 2.21 | |
Ir | Information ratio | -0.09 |
Santhera Pharmaceuticals Volatility Alert
Santhera Pharmaceuticals Holding exhibits very low volatility with skewness of -0.06 and kurtosis of 3.95. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Santhera Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Santhera Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Santhera Pharmaceuticals Fundamentals Vs Peers
Comparing Santhera Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Santhera Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Santhera Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Santhera Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Santhera Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Santhera Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Santhera Pharmaceuticals to competition |
| Fundamentals | Santhera Pharmaceuticals | Peer Average |
| Return On Equity | -13.16 | -0.31 |
| Return On Asset | -0.49 | -0.14 |
| Operating Margin | (386.18) % | (5.51) % |
| Current Valuation | 58.16 M | 16.62 B |
| Shares Outstanding | 61.81 M | 571.82 M |
| Shares Owned By Insiders | 18.77 % | 10.09 % |
| Shares Owned By Institutions | 3.50 % | 39.21 % |
| Price To Earning | (7.01) X | 28.72 X |
| Price To Book | 30.52 X | 9.51 X |
| Price To Sales | 276.19 X | 11.42 X |
| Revenue | (1.59 M) | 9.43 B |
| Gross Profit | (5.36 M) | 27.38 B |
| EBITDA | (34.57 M) | 3.9 B |
| Net Income | (55.53 M) | 570.98 M |
| Cash And Equivalents | 21.21 M | 2.7 B |
| Cash Per Share | 2.07 X | 5.01 X |
| Total Debt | 27 M | 5.32 B |
| Debt To Equity | 196.00 % | 48.70 % |
| Current Ratio | 2.19 X | 2.16 X |
| Book Value Per Share | (0.26) X | 1.93 K |
| Cash Flow From Operations | (37.36 M) | 971.22 M |
| Earnings Per Share | (1.62) X | 3.12 X |
| Target Price | 4.0 | |
| Number Of Employees | 39 | 18.84 K |
| Beta | 0.8 | -0.15 |
| Market Capitalization | 50.45 M | 19.03 B |
| Total Asset | 91.12 M | 29.47 B |
| Z Score | 0.6 | 8.72 |
| Net Asset | 91.12 M |
Santhera Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Santhera . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Santhera Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Santhera Pharmaceuticals Holding? Buying financial instruments such as Santhera Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Santhera Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Currency Funds Thematic Idea Now
Currency Funds
Funds or Etfs investing in a single currency or combination of currencies from different countries in order to replicate respective foreign exchange markets. The Currency Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Currency Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Santhera Stock Analysis
When running Santhera Pharmaceuticals' price analysis, check to measure Santhera Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santhera Pharmaceuticals is operating at the current time. Most of Santhera Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Santhera Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santhera Pharmaceuticals' price. Additionally, you may evaluate how the addition of Santhera Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.